Armenta Bioscience ApS: Financial statements 2023
CVR: 42358444
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Armenta Bioscience ApS (CVR 42358444) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 568,526 and a net result of DKK -50,267 compared with DKK 6,593 the year before. That is an increase of 7,925.5% compared with the year before. Equity in the 2023 report amounted to DKK -14,112. The company had 2 employees in the financial year.
- Gross Profit
- DKK 568,526
- Profit/Loss
- DKK -50,267
- Equity
- DKK -14,112
- Total Assets
- DKK 90,706
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 569 t. | -50 t. | -14 t. | 2 |
| 2022 | - | 7 t. | 7 t. | 36 t. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Armenta Bioscience ApS has published its annual report for 2022. Gross profit came to DKK 7,084, and the net result was DKK 6,593.
As of March 3, 2023, David Valbjørn Christensen is registered as director of Armenta Bioscience ApS.
As of March 3, 2023, Josef Christensen is registered as director of Armenta Bioscience ApS.
About Armenta Bioscience ApS
Armenta Bioscience ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Gephion Bio ApS and Meat Tomorrow ApS. The management consists of Matias Heide Ankjær and David Valbjørn Christensen. The company's owners include Accelerace Invest II K/S, Kempf ApS and Niklis Holdings ApS. In 2025, the company reported a gross profit of DKK -676,873 and a net result of DKK -1,433,453 compared with DKK -1,393,964 the year before. Equity in the 2025 report amounted to DKK 1,283,993.